VANNUCCHI, ALESSANDRO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.081
EU - Europa 17.493
AS - Asia 2.708
AF - Africa 33
OC - Oceania 29
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 46.362
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.003
PL - Polonia 8.016
IE - Irlanda 2.068
IT - Italia 2.035
SE - Svezia 1.717
RU - Federazione Russa 977
HK - Hong Kong 951
CN - Cina 723
DE - Germania 622
UA - Ucraina 588
FI - Finlandia 435
SG - Singapore 395
CH - Svizzera 380
GB - Regno Unito 335
VN - Vietnam 146
TR - Turchia 139
JO - Giordania 133
FR - Francia 122
CA - Canada 78
ES - Italia 76
IN - India 67
KR - Corea 61
AT - Austria 38
BE - Belgio 33
TW - Taiwan 25
AE - Emirati Arabi Uniti 21
NL - Olanda 21
AU - Australia 20
JP - Giappone 17
SC - Seychelles 11
MU - Mauritius 9
NZ - Nuova Zelanda 9
ID - Indonesia 8
RO - Romania 7
BR - Brasile 6
BG - Bulgaria 5
EG - Egitto 5
IR - Iran 5
DK - Danimarca 4
EC - Ecuador 4
EU - Europa 4
GR - Grecia 4
ZA - Sudafrica 4
BY - Bielorussia 3
CL - Cile 2
CO - Colombia 2
IQ - Iraq 2
KE - Kenya 2
KZ - Kazakistan 2
LK - Sri Lanka 2
PH - Filippine 2
RS - Serbia 2
TH - Thailandia 2
AO - Angola 1
AZ - Azerbaigian 1
BD - Bangladesh 1
EE - Estonia 1
GE - Georgia 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
PK - Pakistan 1
SD - Sudan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 46.362
Salva come PNG Salva come JPEG
Città #
Warsaw 8.004
Fairfield 4.750
Ashburn 2.261
Woodbridge 2.159
Dublin 2.063
Seattle 2.016
Chandler 1.845
Cambridge 1.812
Houston 1.689
Wilmington 1.582
Jacksonville 995
Altamura 821
Lawrence 793
Ann Arbor 732
Princeton 657
Hong Kong 453
Boston 420
Bern 379
Beijing 336
Boardman 289
Florence 268
San Diego 268
Medford 250
Buffalo 215
Singapore 200
Moscow 179
Bremen 163
Shanghai 151
Dong Ket 128
New York 125
Izmir 112
Norwalk 87
Hillsboro 77
Kent 70
Falls Church 66
Barcelona 62
Phoenix 59
Andover 54
London 49
Rome 47
Toronto 47
Milan 46
West Jordan 45
Los Angeles 43
Pune 40
Salerno 39
Seoul 39
Vienna 38
Dearborn 37
Brussels 33
Auburn Hills 31
Redwood City 23
Washington 23
Verona 22
Abu Dhabi 19
Bari 17
Old Bridge 16
Fiesole 15
Redmond 15
Taipei 14
Seongnam 13
Sesto Fiorentino 13
Frankfurt Am Main 12
Guangzhou 12
Laurel 12
San Mateo 12
Hefei 11
Lappeenranta 11
Sydney 11
Catania 10
Nanjing 10
Naples 10
Siena 10
Acton 9
Hangzhou 9
Helsinki 9
Kilburn 9
San Jose 9
Chicago 8
Fuzhou 8
Napoli 8
Pisa 8
Romainville 8
Southwark 8
Wuhan 8
Gdansk 7
Montreal 7
Munich 7
New Bedfont 7
Ottawa 7
Prescot 7
Tappahannock 7
Turin 7
Castelliri 6
Chiswick 6
Cortona 6
Frankfurt am Main 6
Iffendic 6
Pian di Scò 6
Prato 6
Totale 37.634
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 288
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis 285
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 258
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 252
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 248
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 246
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 246
Advances in understanding and management of myeloproliferative neoplasms 243
HDAC1 controls CIP2A transcription in human colorectal cancer cells 243
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 242
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 240
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 237
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 235
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 235
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 233
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 233
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 233
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 232
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 229
EZH2 mutational status predicts poor survival in myelofibrosis. 225
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 224
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 223
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 223
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 222
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 218
Effect of mutation order on myeloproliferative neoplasms 218
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 217
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis 217
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis 217
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 216
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 216
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 216
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 214
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. 214
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. 213
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 212
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium 211
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 211
Chronic myeloproliferative neoplasms: a collaborative approach. 209
Cardiovascular events and intensity of treatment in polycythemia vera. 208
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 207
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms 207
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 207
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 207
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. 204
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 204
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. 203
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 195
Clinical significance of genetic aberrations in secondary acute myeloid leukemia 194
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. 194
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 188
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis. 183
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis. 182
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis 181
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 179
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells 177
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 165
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone 165
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 152
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 151
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 150
MPN Score 149
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 145
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 136
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6 132
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis 131
The european hematology association roadmap for european hematology research: A consensus document 130
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 129
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 129
From leeches to personalized medicine: Evolving concepts in the management of polycythemia vera 123
STAT1 activation in association with JAK2 exon 12 mutations 123
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 122
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 117
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 116
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 116
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial 116
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 114
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 113
Circ RNAs are here to stay: A perspective on the MLL recombinome 113
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 113
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 112
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 111
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 108
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 107
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 106
Mutations and prognosis in primary myelofibrosis. 105
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 105
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion 105
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. 104
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet 104
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. 104
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 103
Leukocytosis and risk stratification assessment in essential thrombocythemia. 102
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 102
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 102
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis 101
Insights into JAK2-V617F mutation in CML. 101
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 101
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis 101
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 101
Totale 17.549
Salva come PNG Salva come JPEG
Categoria #
all - tutte 148.223
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 148.223
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011.074 0 789 274 995 1.391 1.491 1.365 1.562 1.291 731 952 233
2020/20216.813 561 631 408 966 324 680 278 565 611 860 449 480
2021/20223.865 123 347 366 150 112 150 144 426 193 140 617 1.097
2022/20239.774 1.015 2.017 415 743 701 1.713 1.116 494 737 96 264 463
2023/20243.728 159 405 685 194 329 464 115 712 67 261 188 149
2024/20251.258 898 360 0 0 0 0 0 0 0 0 0 0
Totale 47.189